B2BROKER
14.12.2021 11:02:59 CET | Business Wire | Press release
B2Broker , a leading technology and liquidity provider within the Forex/CFDs and Digital Currency industries, has confirmed that it has expanded its global reach by establishing a presence in the heavily EU regulated Forex /CFDs market through B2Prime , a Cyprus based Financial Institution authorised and regulated by the Cyprus Securities and Exchange Commission (CySEC).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211214005172/en/
B2Broker now has a vested interest in B2Prime after fulfilling the necessary legal requirements for the required ownership changes. The new owners of B2Prime are Arthur Azizov, founder of B2Broker Group of Companies and Evgeniya Mykulyak, co-founder of B2Broker Group of Companies. Nick Chrysochos becomes the CEO of B2Prime. The move confirms the group’s commitment to providing its investment related services on a global scale through a Liquidity Provider regulated by one of the most well respected and recognised Financial Market Supervisory Authorities.
About B2Prime
B2Prime is a global regulated Prime of Prime (PoP) Multi-Asset Liquidity Provider for institutional and professional clients across the whole spectrum of the financial markets. Its core investment services consist of leveraged derivative products in CFDs (Forex, metals, commodities, shares, indices and cryptocurrencies).
B2Broker Group of Companies
B2Broker is a global brand with a solid reputation in the B2B sphere as one of the most in-demand technology and liquidity providers for Forex and crypto brokers, crypto exchanges and other financial services entities. The company offers a wide range of services including Crypto/Forex/CFD liquidity, Crypto/Forex Broker turnkey solutions, crypto payment processing (B2BinPay), MT4/5 white label solutions, B2Core (Trader’s Room) , B2Trader (Matching Engine) and liquidity on over 800 trading instruments across the entire spectrum of assets.
Headquartered in Moscow, B2Broker has several years of operational experience with 10 offices in 8 countries across Russia, Europe, Asia and MENA. A total of 7 licences to its name including FCA, AEMI and Central Bank of Russia, allows B2Broker to serve clients across 50 countries, offering Forex liquidity distribution and a range of other services to the Forex, Crypto and Securities industries. The company has secured a large portfolio of well-known global clients in the financial services industry with plans to further increase company representation and visibility across the globe.
What the News Means For Clients
CySEC is Cyprus’ financial regulator which provides a framework within which the country’s licenced financial services firms are obliged to operate. As a CySEC regulated broker, B2Prime must adhere to the strictest financial market regulatory standards, including capital adequacy requirements, segregation of client funds and transparency of business operations.
Clients residing in the EU, UK and several other 3rd country jurisdictions can now be safely onboarded under the EU MiFID II regulatory standards. B2Broker can now expand its footprint in the European Union and provide clients with the opportunity to experience the organisation’s full product and service offering through an EU financial services brokerage licence, while positioning itself on an accelerated global growth path.
B2Broker Group of Companies CEO, Arthur Azizov, commented, “We are delighted that B2Prime has secured CySEC approval. The licence gives us the scope to provide institutional grade liquidity to clients in over 30 countries. Meanwhile, our clients will be able to benefit from an enhanced level of protection, safe in the knowledge that they have the backing of a world-leading, multi-regulated technology and liquidity provider. We expect that having now secured CySEC’s authorisation to provide our investment liquidity services, it will help us establish our place in this space as one of the strongest and most reliable organisations where clients can feel at ease when trading with us”.
B2Prime’s owner and Executive Director, Evgeniya Mykulyak, co-founder of B2Broker Group commented, “My vision is to make B2Prime one of the most solid and reliable financial services companies in the Forex space with a high standard of service provision being our key focus. I look forward to exploring the many new opportunities available to us in Europe and to welcoming new clients on board. Our efforts will include the introduction of new trading platforms for connection as well as the continued rollout of our Prime of Prime liquidity services. We are already building a strong liquidity provision network in the European market and have established relationships with major Prime Brokers. Furthermore, we plan to become a member of several exchanges, all in all, making B2Prime a major player in the financial services industry”.
B2Prime CEO, Nick Chrysochos added, “With Artur Azizov’s long experience and solid credentials in the Forex and Crypto space and Evgeniya Mykulyak’s deep industry know-how and clear vision for the company, we will be able to provide advanced, cutting-edge technology so that our clients can trade with the reassurance of knowing that their trading activities are managed by a reputable firm that adheres to the most stringent regulatory standards of CySEC”.
Final Word
BPrime has already opened the door to receiving new clients and can connect brokers via OneZero, MT5 and PrimeXM platforms to offer trading on 115 Forex pairs including 22 Crypto CFD pairs, Spot Metals, Indices and Spot Energies.
The latest licence acquisition is a part of B2Broker’s overall strategic plan to have a presence in all the major jurisdictions, focusing on the goal of becoming a global liquidity provider. The corresponding launch of commercial operations in Cyprus is also a testament to the company’s ongoing success and growth, where it will continue to provide some of the best liquidity and trading services in the industry.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005172/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom